About CRMI Company

China Regenerative Medicine International Limited (“China Regenerative Medicine”) was incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange on July 18, 2001. The stock code is 8158. The main business of regenerative medicine in China is to engage in research and development of biomedical products and healthcare products and medical technology; provide production and sales of tissue engineering products and derivatives; and sell and distribute medical products and equipment. As a leader in the industrialization of biological tissue engineering and regenerative medicine in China, the company focuses on four major business areas, namely cell and stem cell therapy; tissue engineering; beauty and health care; and medical equipment and other services. Our current production sites are located in Xi'an, Shaanxi, Shenzhen, Guangdong, Suzhou, Jiangsu, and Tianjin. Local businesses are operated by indirect wholly-owned subsidiaries Shaanxi Airskin Engineering Co., Ltd. (“Shaanxi Airskin”), Shaanxi Ruisheng Biotechnology Co., Ltd., Aokai (Suzhou) Biotechnology Co., Ltd., and Tianjin Weikai Biotechnology Co., Ltd. Shaanxi Airskin is the first private enterprise specializing in research and development of tissue engineering in China. Shaanxi Airskin's tissue engineering products and commercialization have been identified as one of the key projects of the “863 Plan” of the Chinese Ministry of Science and Technology. The tissue-engineered skin product “Skin Safety” won the first prize of the National Science and Technology Progress Award in 2011, and was approved by the China Food and Drug Administration (“State Drug Administration”) as the country's first tissue-engineered skin product containing living human cells. Our plants in Xi'an and Shenzhen are responsible for developing and producing our organizational engineering products. The factory in Xi'an is mainly responsible for tissue engineering skin, that is, “skin care” and mucous membranes and derived products, while the Shenzhen plant mainly provides production and research work for the bioengineered corneal “Aisin Eye.” The bioengineered cornea “Aixin Eye”, independently developed by China's regenerative medicine and has complete independent intellectual property rights, was approved for sale by the State Drug Administration in April 2015, making it the world's first bioengineered corneal product. The Suzhou plant provides clinical-grade cell production and processing services, while the plant in Tianjin mainly provides contract technical research services and the design, manufacture and sale of preclinical-level perfusion cell culture machines for relevant institutions. The Group will continue to explore high-quality medical products and technologies, and focus on therapeutic innovation in regenerative medicine. To promote the development of regenerative medicine, China's regenerative medicine will establish regenerative medicine cell therapy centers in various cities such as Suzhou and Tianjin. At the same time, China's regenerative medicine is seizing the opportunity to establish long-term cooperative relationships with the world's leading institutions on the development of cell and stem cell therapies. In 2014, Regenerative Medicine in China was the first biotech company to establish a technology center for cell and stem cell therapy at Oxford University. Since the second quarter of 2015, China's regenerative medicine has begun to design and establish a Chinese stem cell clinical application center located in Hong Kong Science Park, Shatin, Hong Kong. The center will provide clinical-grade cell-related services and products. Furthermore, in the third quarter of 2015, China Regenerative Medicine carried out the establishment of five adult tissue cell banks in areas near existing production facilities and in Hong Kong. Through cooperation with world-class institutions such as the University of Oxford and leading universities in Hong Kong, we have obtained relevant expertise from them, and provided support for the application of cell and stem cell therapy to hospitals across the country at the centers mentioned above. Regenerative medicine in China will continue to explore new fields of human life science and lead global medical innovation. The Group will continue to strive to use its resources and expertise to promote product development, commercialize products and develop market potential. While improving human health and life is the mission that Chinese regenerative medicine has always adhered to, we will also strive to enhance long-term shareholder value.